Years of life that could be saved from prevention of hepatocellular carcinoma

Cucchetti, Alessandro; Trevisani, Franco; Bucci, Laura; Ravaioli, Matteo; Farinati, Fabio; Giannini, Edoardo G.; Ciccarese, Francesca; Piscaglia, Fabio; Rapaccini, Gian Ludovico; Marco, Maria Di; Caturelli, Eugenio; Zoli, Marco; Borzio, Franco; Sacco, Rodolfo; Maida, Marcello; Felder, Martina; Morisco, Filomena; Gasbarrini, Antonio; Gemini, S; Foschi, Francesco Giuseppe; Missale, Gabriele; Masotto, Alberto; Affronti, Andrea; Bernardi, Mauro; Pinna, Antonio Daniele; Bolondi, Luigi; Biselli, Maurizio; Caraceni, Paolo; Domenicali, Marco; Gramenzi, Annagiulia; Magalotti, Donatella; Pecorelli, Anna; Serra, Carla; Venerandi, Laura; Gazzola, Alessia; Murer, F.; Pozzan, C.; Vanin, V.; Poggio, P. Del; Olmi, Stefano; Balsamo, Claudia; Vavassori, Elena; Benvegnù, Luisa; Cappelli, Alberta; Golfieri, Rita; Mosconi, Cristina; Renzulli, Matteo; Bosco, Giulia; Roselli, Paola; Dell’Isola, Serena; Lalungo, Anna Maria; Rastrelli, Elena; Moscatelli, Alessandro; Pellegatta, Gaia; Picciotto, Antonino; Savarino, Vincenzo; Barcellona, Maria Rosa; Cammà, Calogero; Cabibbo, Giuseppe; Costantino, Andrea; Virdone, Roberto; Mega, Andrea; Rinninella, Emanuele; Mismas, V.; Dall’Aglio, Anna Chiara; Feletti, Valentina; Lanzi, Arianna; Cappa, Federica Mirici; Neri, Elga; Stefanini, Giuseppe Francesco; Tamberi, Stefano; Biasini, Elisabetta; Porro, E.; Guarino, Maria; Svegliati‐Baroni, Gianluca; Schiadà, Laura; Chiaramonte, M.; Marchetti, Fabiana; Valerio, Matteo

doi:10.1111/apt.13554

Cited by 24 publications

(24 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The curve of logit transformation of the relative survival between the index cohort and the reference population would follow an approximately straight line if the excess hazard of the patients remains constant over time (Fang, Chang, Hsu, et al, ). This method has been successfully validated with simulation data and has been used to analyze real data in several studies (e.g., Cucchetti, Trevisani, Bucci, et al, , Hung et al, ‐, , H. Y. Lee et al, , Yang, Lee, Hsu, et al, ; Yang, Lai, Chang, et al, ). The assumption of an excess constant hazard, however, is usually untestable with a limited observed time period, because how closely the curve of logit‐transformed relative survival approaches a straight line is uncertain.…”

Section: Introductionmentioning

confidence: 99%

Estimating lifetime medical costs from censored claims data

Hwang

Lee

et al. 2017

Health Economics

View full text Add to dashboard Cite

Claims databases consisting of routinely collected longitudinal records of medical expenditures are increasingly utilized for estimating expected medical costs of patients with a specific condition. Survival data of the patients of interest are usually highly censored, and observed expenditures are incomplete. In this study, we propose a survival-adjusted estimator for estimating mean lifetime costs, which integrates the product of the survival function and the mean cost function over the lifetime horizon. The survival function is estimated by a new algorithm of rolling extrapolation, aided by external information of age- and sex-matched referents simulated from national vital statistics. The mean cost function is estimated by a weighted average of mean expenditures of patients in a number of months prior to their death, of which the number could be determined by observed costs in their final months, and the weights depend on extrapolated hazards. We evaluate the performance of the proposed approach in comparison with that of a popular method using simulated data under various scenarios and 2 cohorts of intracerebral hemorrhage and ischemic stroke patients with a maximum follow-up of 13 years and conclude that our new method estimates the mean lifetime costs more accurately.

show abstract

Section: Introductionmentioning

confidence: 99%

Estimating lifetime medical costs from censored claims data

Hwang

Lee

et al. 2017

Health Economics

View full text Add to dashboard Cite

show abstract

“…To view this article visit https://doi.org/10.1111/apt.13813. DEAR SIR, We read with interest the recent study by Cole et al 1 In the article, proton pump inhibitors (PPIs) prescription was associated with severity of cirrhosis, even though no significant relationship between PPIs and mortality was observed. 1 Safety of PPIs in patients with cirrhosis has been recently questioned as studies revealed association between these drugs not only with spontaneous bacterial peritonitis but also with worse prognosis.…”

Section: Linked Contentmentioning

confidence: 99%

“…1 Clinical response and remission rates were 61% and 24% in Crohn's disease and 57% and 24% in ulcerative colitis, respectively, after fourteen weeks of VDZ treatment. The three most common adverse events were joint pain, acne and nasopharyngitis.…”

mentioning

confidence: 93%

Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis

Hartery

O’Reilly

Houlihan

et al. 2016

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…Notably, there is a decrease of infection-related cases but an increase in cases related to other risk factors, with NASH being the predominant factor [3]. For younger patients, HCC results in the loss of a considerable number of years-of-life with an estimated lifespan loss of 19.1 years shown in a recent study [4]. The knowledge about risk factors for HCC provides the opportunity and chance for the development and implementation of preventative strategies aiming at an efficient and effective prevention of HCC to decrease the worldwide burden of the disease [5].…”

Section: Introductionmentioning

confidence: 99%

Prevention of Hepatocellular Carcinoma

Schütte

Balbisi

Malfertheiner

2016

Gastrointest Tumors

View full text Add to dashboard Cite

The epidemiology of hepatocellular carcinoma (HCC) has significantly changed throughout the past decade and will continue to do so in the future as a consequence of effective primary prevention and treatment of virus-related liver diseases. However, other risk factors for HCC are constantly on the rise, including alcoholic liver disease and nonalcoholic fatty liver disease. The knowledge on these and further risk factors associated with an increased risk of HCC provide the opportunity and chance for the development and implementation of successful preventive strategies to decrease the worldwide burden of HCC. This mini-review gives a short overview on current strategies in primary, secondary, and tertiary prevention of HCC.

show abstract

Years of life that could be saved from prevention of hepatocellular carcinoma

Abstract: Hepatocellular carcinoma occurrence results in the loss of a considerable number of years-of-life, especially for younger patients. In recent years, the increased possibility of effectively treating this tumour has improved life expectancy, thus reducing years-of-life lost.

Cited by 24 publications

References 25 publications

Estimating lifetime medical costs from censored claims data

Estimating lifetime medical costs from censored claims data

Letter: vedolizumab for the management of inflammatory bowel disease in patients after liver transplantation for primary sclerosing cholangitis

Prevention of Hepatocellular Carcinoma

Contact Info

Product

Resources

About